Meropenem pharmacokinetics in the newborn

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F09%3A5480" target="_blank" >RIV/00216208:11110/09:5480 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/09:5480 RIV/00216208:11150/09:10051673

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Meropenem pharmacokinetics in the newborn

Popis výsledku v původním jazyce

We studied meropenem in 23 pre-term (gestational age, 29 to 36 weeks) and 15 full-term (gestational age 37 to 42 weeks) neonates. Meropenem doses of 10, 20 and 40 mg/kg were administered as single doses (30-min intravenous infusion) on a random basis. Blood was obtained for determining the meropenem concentration nine times. Each child required other antimicrobials for proven/suspected bacterial infections. Samples were assayed obtained by employing the BigNPAG program. A Monte Carlo simulation was performed using the creatinine clearance nt organisms were to be treated (MIC of 4 to 8 mg/liter), the 40-mg/kg dose and a prolonged infusion was favored. Treating clinicians need to balance dose choices for optimizing target attainment against potential toxicity. These findings require validation in clinical circumstances.

Název v anglickém jazyce

Meropenem pharmacokinetics in the newborn

Popis výsledku anglicky

We studied meropenem in 23 pre-term (gestational age, 29 to 36 weeks) and 15 full-term (gestational age 37 to 42 weeks) neonates. Meropenem doses of 10, 20 and 40 mg/kg were administered as single doses (30-min intravenous infusion) on a random basis. Blood was obtained for determining the meropenem concentration nine times. Each child required other antimicrobials for proven/suspected bacterial infections. Samples were assayed obtained by employing the BigNPAG program. A Monte Carlo simulation was performed using the creatinine clearance nt organisms were to be treated (MIC of 4 to 8 mg/liter), the 40-mg/kg dose and a prolonged infusion was favored. Treating clinicians need to balance dose choices for optimizing target attainment against potential toxicity. These findings require validation in clinical circumstances.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FG - Pediatrie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Antimicrobial Agents and Chemotherapy

ISSN

0066-4804

e-ISSN

—

Svazek periodika

53

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

—

Kód UT WoS článku

000270014200034

EID výsledku v databázi Scopus

—